Dr. Moxit Shah, DM Endocrinologist
Diabetes, Thyroid & Weight Loss Specialist in Ahmedabad
GLP-1 medicines have become one of the most important advances in the treatment of type 2 diabetes and obesity.
Medicines such as semaglutide, dulaglutide and liraglutide, as well as the dual GIP/GLP-1 medicine tirzepatide, can do much more than lower blood sugar. Depending on the medicine and the patient, they can also help with weight loss, cardiovascular risk reduction, kidney health and metabolic health.
The American Diabetes Association’s 2026 Standards recommend GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists with demonstrated benefits in appropriate people with type 2 diabetes, particularly when obesity, cardiovascular disease or chronic kidney disease is also present.
But are GLP-1 medicines suitable for everyone with diabetes?
No.
The right treatment depends on your diabetes, weight, kidney function, cardiovascular risk, other medicines, side effects and overall health.
What Are GLP-1 Medicines?
GLP-1 stands for glucagon-like peptide-1.
It is a naturally occurring hormone produced in the body that plays an important role in:
- Blood glucose regulation
- Insulin secretion
- Glucagon regulation
- Appetite
- Satiety
- Gastric emptying
GLP-1 medicines mimic some of these effects.
They can increase glucose-dependent insulin secretion, reduce inappropriate glucagon secretion, slow gastric emptying and increase feelings of fullness.
This combination makes them useful for both diabetes management and weight management.
Which GLP-1 Medicines Are Available?
GLP-1-based treatments include several medicines.
GLP-1 receptor agonists
Examples include:
- Semaglutide
- Dulaglutide
- Liraglutide
Dual GIP/GLP-1 receptor agonist
- Tirzepatide
Tirzepatide is technically not a pure GLP-1 receptor agonist. It activates both GIP and GLP-1 receptors.
Different formulations and brands have different approved indications.
How Do GLP-1 Medicines Lower Blood Sugar?
GLP-1-based medicines work through several mechanisms.
1. Increase insulin secretion when glucose is elevated
They help the pancreas release insulin in a glucose-dependent manner.
2. Reduce glucagon
Glucagon increases blood glucose. GLP-1-based medicines can reduce inappropriate glucagon secretion.
3. Slow gastric emptying
Food can leave the stomach more slowly, contributing to a slower rise in blood glucose and greater fullness.
4. Reduce appetite
Many patients eat less because they feel satisfied sooner.
The overall effect can be improved glucose control and, with some medicines, substantial weight loss.
GLP-1 Medicines Are Not Just “Sugar-Lowering Injections”
This is one of the most important changes in modern diabetes treatment.
In appropriate patients, GLP-1-based therapy may provide benefits beyond HbA1c.
Depending on the specific drug and clinical situation, benefits may include:
- Weight loss
- Cardiovascular risk reduction
- Kidney protection
- Improvement in metabolic health
- Improvement in some obesity-related complications
The ADA 2026 Standards recommend GLP-1 receptor agonists with demonstrated cardiovascular benefit in appropriate people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk.
GLP-1 Medicines and Weight Loss
One reason GLP-1 medicines have become so popular is their effect on body weight.
They can:
- Reduce hunger
- Increase fullness
- Reduce food intake
- Reduce food cravings in some patients
- Support sustained weight reduction
Among diabetes medicines, the ADA 2026 Standards identify tirzepatide and semaglutide as having very high efficacy for both glucose lowering and weight loss.
However, individual response varies.
A medicine that produces excellent weight loss in one patient may be less effective or less well tolerated in another.
GLP-1 vs Tirzepatide: Are They the Same?
No.
Semaglutide
Semaglutide primarily activates the GLP-1 receptor.
Tirzepatide
Tirzepatide activates:
GIP + GLP-1 receptors
This dual mechanism contributes to its strong effects on glucose control and body weight.
If you want to understand their differences in more detail, see our article:
Semaglutide vs Tirzepatide for Weight Loss: Which Is Better?
Who With Diabetes May Benefit From GLP-1 Treatment?
GLP-1-based treatment may be particularly useful for people with type 2 diabetes who also have:
- Overweight or obesity
- Established cardiovascular disease
- High cardiovascular risk
- Chronic kidney disease
- Difficulty achieving glucose targets
- A need to reduce weight-promoting diabetes medications
The ADA recommends considering GLP-1-based therapies with demonstrated benefits in people with type 2 diabetes and cardiovascular disease, CKD or obesity, depending on the clinical situation.
Do You Need High HbA1c to Take a GLP-1 Medicine?
Not necessarily.
This is an important point.
For certain people with type 2 diabetes and established cardiovascular disease, CKD or high cardiovascular risk, GLP-1 therapy may be recommended irrespective of HbA1c or whether the patient is already taking metformin, when the specific medicine has demonstrated relevant outcome benefits.
Therefore, treatment decisions should not be based only on one HbA1c number.
A doctor should consider the patient’s overall cardiovascular, kidney, metabolic and weight profile.
Can GLP-1 Medicines Be Used With Metformin?
Yes.
Depending on the individual patient, a GLP-1-based medicine may be used:
- With metformin
- Without metformin
- With other diabetes medicines
The ADA emphasizes that GLP-1 or SGLT2 therapies with proven cardiovascular benefits may be indicated for cardiovascular risk reduction independent of metformin use in appropriate patients.
The combination should be individualized.
What About Insulin and GLP-1 Medicines?
GLP-1-based therapy can sometimes be combined with insulin.
This can be particularly useful when:
- Blood glucose remains above target
- Weight gain from insulin is a concern
- The patient has obesity
- A reduction in insulin requirements may be possible
However, combining glucose-lowering medicines requires appropriate medical supervision.
When insulin or sulfonylureas are used, medication adjustments may sometimes be needed to reduce the risk of hypoglycemia.
Do GLP-1 Medicines Cause Low Blood Sugar?
By themselves, GLP-1 medicines generally have a low risk of hypoglycemia.
This is because their insulin-stimulating effect is largely glucose dependent.
However, the risk can increase when they are combined with medicines such as:
- Insulin
- Sulfonylureas
Therefore, medication combinations need to be reviewed by your doctor.
What Are the Common Side Effects?
The most common side effects involve the gastrointestinal system.
These may include:
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Bloating
- Abdominal discomfort
- Feeling full quickly
- Reduced appetite
These symptoms are often more noticeable when treatment is started or the dose is increased.
The ADA recommends dietary strategies such as smaller meals, mindful eating and reducing high-fat or spicy foods when gastrointestinal symptoms occur.
Why Do GLP-1 Medicines Cause Nausea?
Several effects contribute.
GLP-1-based medicines can:
- Slow gastric emptying
- Increase satiety
- Reduce appetite
- Alter gut-brain signaling
If a patient eats a large meal despite feeling full, nausea or abdominal discomfort may become more noticeable.
This is why portion control becomes particularly important.
How Can You Reduce GLP-1 Side Effects?
Some practical strategies include:
Eat smaller meals
Don’t force yourself to finish a large portion if you’re already full.
Eat slowly
Take time to chew and eat.
Limit very fatty meals
Fried and greasy foods may worsen gastrointestinal symptoms.
Stay hydrated
Especially if vomiting or diarrhea occurs.
Increase the dose only as prescribed
Don’t increase your dose faster than recommended.
Tell your doctor about persistent symptoms
Severe or persistent symptoms should not simply be ignored.
Who Should Be Cautious With GLP-1 Medicines?
GLP-1-based treatment is not suitable for everyone.
Your doctor may need to carefully assess you if you have:
- Severe gastrointestinal disease
- Significant gastroparesis
- Previous pancreatitis
- Gallbladder disease
- Certain diabetic eye complications
- Kidney problems
- Pregnancy or plans for pregnancy
- A relevant personal or family history of medullary thyroid carcinoma or MEN2, depending on the medicine
The specific contraindications and warnings depend on the individual product.
GLP-1 Medicines and the Thyroid
You may have heard about a warning concerning thyroid tumors.
This requires some clarification.
For relevant GLP-1 medicines, thyroid C-cell tumors have been observed in rodents. The clinical relevance to humans remains uncertain.
Some products therefore carry contraindications involving:
- Personal history of medullary thyroid carcinoma
- Family history of medullary thyroid carcinoma
- MEN2
This does not mean that everyone with ordinary thyroid disease cannot take a GLP-1 medicine.
For example, having common hypothyroidism or Hashimoto’s thyroiditis is not the same thing as having medullary thyroid carcinoma.
Your endocrinologist can assess your individual risk.
GLP-1 Medicines and the Kidneys
GLP-1-based therapies can be particularly useful in people with type 2 diabetes and CKD when an appropriate agent is selected.
The ADA 2026 Standards recommend a GLP-1 receptor agonist or SGLT2 inhibitor with demonstrated benefit for appropriate people with type 2 diabetes and CKD.
However, severe vomiting or diarrhea can cause dehydration, which can affect kidney function.
Therefore, kidney function may need monitoring in patients who develop significant gastrointestinal adverse effects.
GLP-1 Medicines and the Heart
This is one of the most important developments in diabetes treatment.
Several GLP-1 receptor agonists have demonstrated cardiovascular benefits in people with type 2 diabetes.
The ADA 2026 Standards recommend GLP-1 receptor agonists with demonstrated cardiovascular benefit for appropriate people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk.
This means that the decision to use a GLP-1 medicine may sometimes be about reducing future cardiovascular risk—not just lowering HbA1c.
GLP-1 Medicines and Fatty Liver
People with type 2 diabetes and obesity frequently have metabolic dysfunction-associated steatotic liver disease (MASLD).
The ADA 2026 Standards recommend considering a GLP-1 receptor agonist with demonstrated benefit in MASH or a dual GIP/GLP-1 receptor agonist with potential benefit in appropriate patients with type 2 diabetes, MASLD and overweight/obesity.
This is another example of why metabolic treatment should look beyond blood sugar alone.
Can GLP-1 Medicines Be Used for People Without Diabetes?
Yes.
Some formulations of semaglutide and tirzepatide are approved for chronic weight management in eligible people who do not have diabetes.
The WHO now conditionally recommends certain GLP-1 therapies—including semaglutide and tirzepatide—as part of comprehensive obesity management in adults with obesity.
But eligibility depends on:
- The specific medicine
- Regulatory approval
- BMI and weight-related complications
- Medical history
- Individual risk-benefit assessment
GLP-1 Is Not a “Magic Injection”
This is perhaps the most important message for patients.
Medication can be highly effective, but long-term results are improved when treatment is combined with:
🥗 Healthy nutrition
🏋️ Resistance training
🚶 Regular physical activity
😴 Adequate sleep
📊 Medical monitoring
WHO specifically recommends GLP-1 therapy as part of a comprehensive approach that includes healthy diet, physical activity and professional support.
What Happens If You Stop GLP-1 Treatment?
Weight regain can occur after stopping effective obesity pharmacotherapy.
This is because the biological tendency toward increased appetite and weight regain may persist.
The ADA 2026 Standards note that chronic obesity pharmacotherapy should generally continue beyond achieving weight-loss goals when indicated, because discontinuation often leads to recurrence of weight gain and worsening or re-emergence of cardiometabolic risk factors.
This does not mean everyone must remain on the same treatment forever.
It means the long-term treatment strategy should be planned rather than stopping medication without medical guidance.
What About Muscle Loss?
Significant weight loss can include some loss of lean mass.
Therefore, patients taking GLP-1 medicines should pay attention to:
- Adequate protein
- Resistance exercise
- Physical activity
- Nutritional quality
- Muscle strength
Your goal should be fat loss while preserving muscle as much as possible.
Read our detailed article:
GLP-1 and Muscle Loss: How to Protect Muscle While Losing Weight
Can You Take GLP-1 Medicines Without Medical Supervision?
It is not advisable.
The popularity of semaglutide and tirzepatide has led to increasing use through informal and unverified sources.
WHO has warned about falsified and substandard GLP-1 products and emphasizes regulated distribution and prescribing by qualified healthcare professionals.
The FDA has also reported adverse events associated with compounded semaglutide and tirzepatide products and has raised concerns about dosing and administration errors with compounded products.
Therefore:
Don’t buy an injectable GLP-1 medicine from an unknown online source.
Don’t use someone else’s prescription.
Don’t increase the dose yourself.
GLP-1 Medicines: Who May Benefit Most?
A patient may be an especially good candidate when several factors are present, such as:
Type 2 diabetes + obesity
or
Type 2 diabetes + cardiovascular disease
or
Type 2 diabetes + CKD
or
Type 2 diabetes + significant weight-management needs
But there is no universal “best GLP-1 medicine.”
The choice should consider the entire patient.
Semaglutide vs Tirzepatide: Which Should You Choose?
The answer depends on your goals.
Tirzepatide and semaglutide are among the most effective therapies for glucose lowering and weight reduction.
However, the best medicine depends on:
- HbA1c
- Weight
- BMI
- Cardiovascular disease
- Kidney disease
- Liver disease
- Other medications
- Gastrointestinal tolerance
- Cost and availability
- Treatment goals
- Patient preference
Don’t choose a medicine simply because it is popular on social media.
10 Important Things to Know Before Starting GLP-1 Treatment
1. GLP-1 medicines are prescription treatments.
2. They can lower blood glucose.
3. Many can reduce appetite and body weight.
4. Gastrointestinal side effects are common.
5. Dose escalation should be individualized.
6. They may provide cardiovascular or kidney benefits in appropriate patients.
7. They should be combined with healthy lifestyle habits.
8. Protein and resistance training are important during weight loss.
9. Don’t stop or change treatment without medical advice.
10. Long-term treatment planning matters.
Frequently Asked Questions
Are GLP-1 medicines only for weight loss?
No. GLP-1 receptor agonists were originally developed for type 2 diabetes and remain important diabetes treatments. Some formulations are also approved for chronic weight management.
Is Mounjaro a GLP-1 medicine?
Mounjaro contains tirzepatide, which activates both GIP and GLP-1 receptors.
Is Ozempic a GLP-1 medicine?
Yes. Ozempic contains semaglutide, a GLP-1 receptor agonist.
Can a person with diabetes and normal weight take GLP-1 medicine?
Potentially, depending on the individual’s diabetes, cardiovascular and kidney risk and other treatment considerations. Weight is not the only factor determining whether a GLP-1 medicine is appropriate.
Can GLP-1 medicines replace metformin?
Sometimes treatment may be changed or combined depending on the patient’s circumstances. There is no universal rule that everyone should take—or stop—metformin when starting GLP-1 therapy.
Do GLP-1 medicines cause hypoglycemia?
The risk is generally low when used alone, but it can increase when combined with insulin or sulfonylureas.
Can I take GLP-1 medicine if I have thyroid disease?
Common thyroid disorders do not automatically exclude GLP-1 therapy. However, specific contraindications involving medullary thyroid carcinoma and MEN2 need to be considered for relevant medicines.
Can GLP-1 medicines protect the heart?
Several GLP-1 receptor agonists have demonstrated cardiovascular benefits in people with type 2 diabetes. The appropriate medicine depends on the individual patient’s clinical profile.
Final Takeaway
GLP-1 medicines have changed the way we approach type 2 diabetes, obesity and metabolic disease.
Their benefits can extend beyond lowering blood sugar.
For appropriately selected patients, GLP-1-based treatment can help with:
Blood glucose → Weight → Cardiovascular risk → Kidney health → Metabolic health
But these medicines are not suitable for everyone.
The right approach is:
Correct patient + correct medicine + correct dose + proper monitoring + healthy lifestyle
If you are considering semaglutide, tirzepatide or another GLP-1-based treatment, speak with an endocrinologist before starting or changing therapy.
GLP-1 Treatment in Ahmedabad
Dr. Moxit Shah, DM Endocrinologist, provides comprehensive care for diabetes, obesity, thyroid disorders and metabolic diseases in Ahmedabad.
At Vishuddha Endocrine Clinic, GLP-1 treatment is individualized according to your diabetes control, weight, cardiovascular risk, kidney function, medications and treatment goals.
Vishuddha Endocrine Clinic
📍 Ahmedabad
📞 +91 99799 92797
